Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:57:09.735Z.
Calculation as of: 2026-10-06T19:57:09.735Z.
Quote observation: 2026-10-06T19:55:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
TuHURA Biosciences, Inc.
Market Cap
$124.50M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $124.50M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $125.44M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.98M | N/A |
| BGM Group Ltd. (BGM)vs › | $121.55M | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $127.66M | N/A |
| Cibus, Inc. (CBUS)vs › | $119.84M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $128.37M | N/A |
| Seer, Inc. (SEER)vs › | $120.13M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.28M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
